Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study

Authors Jahnz-Różyk K, Szepiel P

Received 7 November 2014

Accepted for publication 21 January 2015

Published 18 March 2015 Volume 2015:10(1) Pages 613—623

DOI https://doi.org/10.2147/COPD.S77144

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Karina Jahnz-Różyk,1 Pawel Szepiel2

1Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland; 2Boehringer Ingelheim Sp. z o.o., Warsaw, Poland


Background: Long-acting inhaled bronchodilators, including anticholinergic tiotropium, are recommended for the maintenance therapy of chronic obstructive pulmonary disease (COPD). It has been shown in a number of studies that treatment with tiotropium alleviates symptoms, improves exercise tolerance, health status, and reduces exacerbations in patients with moderate to very severe stage COPD.
Aim: The aim of this noninterventional study was to observe the early effects of the maintenance treatment with tiotropium in patients with COPD of different severities, who had been previously treated on a regular basis, or as required, with at least one short-acting bronchodilator, in a real-life setting in Poland. The effect of the treatment was assessed through the collection of COPD Assessment Test (CAT) data.
Patients and methods: The MATHS clinical study was an observational, noninterventional, open-label, prospective, uncontrolled, single-arm, postmarketing, surveillance, real-life study conducted with the involvement of 236 pulmonology clinics based in Poland. The tiotropium observational period was 3 months. The health and COPD status was measured with the CAT questionnaire. The primary efficacy endpoint was the mean change from the baseline in the total CAT score at the end of the 3-month observational period.
Results: Patients treated with 18 µg of tiotropium once daily for 3 months showed a statistically significant result, with a clinically meaningful mean reduction (improvement) of 7.0 points in the total CAT score. The improvement was slightly greater in patients with more severe COPD; the mean change in the total CAT score was 7.6 in the subgroup of patients with more severe COPD and 6.7 points in the subgroup of patients with moderate COPD.
Conclusion: Results of this real-life study provide further support for the use of tiotropium as a first-line maintenance treatment for patients with COPD of different severities in Poland.

Keywords: Spiriva® HandiHaler®, chronic obstructive pulmonary disease, GOLD classification, CAT

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes

Zhang JQ, Zhang JQ, Liu H, Zhao ZH, Fang LZ, Liu L, Fu WP, Shu JK, Feng JG, Dai LM

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:917-923

Published Date: 13 May 2015

A bibliometric analysis of the 100 most influential papers on COPD

Gu WC, Yuan YP, Yang H, Qi GS, Jin XY, Yan J

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:667-676

Published Date: 25 March 2015

Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients

Nascimento ESP, Sampaio LMM, Peixoto-Souza FS, Dias FD, Gomes ELFD, Greiffo FR, Ligeiro de Oliveira AP, Stirbulov R, Vieira RP, Costa D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:645-653

Published Date: 23 March 2015

Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study

Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:603-611

Published Date: 18 March 2015

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

Nishijima Y, Minami S, Yamamoto S, Ogata Y, Koba T, Futami S, Komuta K

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:439-444

Published Date: 27 February 2015

Antibiotics against Pseudomonas aeruginosa for COPD exacerbation in ICU: a 10-year retrospective study

Planquette B, Péron J, Dubuisson E, Roujansky A, Laurent V, Le Monnier A, Legriel S, Ferre A, Bruneel F, Chiles PG, Bedos JP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:379-388

Published Date: 17 February 2015

Whole-body vibration improves functional capacity and quality of life in patients with severe chronic obstructive pulmonary disease (COPD): a pilot study

Braz Júnior DS, Dornelas de Andrade A, Teixeira AS, Cavalcanti CA, Morais AB, Marinho PE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:125-132

Published Date: 12 January 2015